ABVC - What In The World Is Going On With ABVC BioPharma Stock? | Benzinga
ABVC Biopharma Inc (NASDAQ: ABVC) shares are trading higher by 309% to $3.48 Thursday morning after the company announced it entered into a term sheet to license the global rights of CNS drugs with the indications of MDD and ADHD to AiBtl BioPharma at the valuation of $667 million.
What Happened?
ABVC has announced a multi-year licensing agreement with AiBtl BioPharma for their CNS drugs targeting Major Depressive Disorder (MDD) and Attention Deficit Hyperactivity Disorder (ADHD). The ...